Pieter-Jan De Kam, Matthias F Kramer, Mohamed H Shamji, Kemi Oluwayi, Matthew D Heath, Erika Jensen-Jarolim, Markus H Berger, Uwe E Berger, Anke Graessel, Fiona Sellwood, Stefan Zielen, Christian Vogelberg, Petra Zieglmayer, Ralph Mösges, Ludger Klimek, Lawrence M DuBuske, Wayne G Shreffler, Jonathan A Bernstein, Thomas M Kündig, Murray A Skinner
The concept of treatment of an allergy with the offending allergen was introduced more than a century ago. Allergen immunotherapy (AIT) is the only disease modifying treatment of allergic diseases caused by inhalational allergens and insect venoms. Despite this, only few AIT products have reached licensure in the US or an official marketing authorization status in European countries. Moreover, most of these AIT products are provided on an individual patient basis as named patient products (NPP) in Europe, while individualized preparations of (mixed) allergenic extract vials for subcutaneous administration (compounding) is common practice in the US...
September 2021: World Allergy Organization Journal